Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ista Pharmaceuticals Inc.

Division of Bausch Health Companies Inc.

Latest From Ista Pharmaceuticals Inc.

What next for acquisition-hungry Valeant?

Valeant Pharmaceuticals' CEO J Michael Pearson was in Asia when the news broke at the start of this week that Valeant had lost out to Actavis in its bid for Allergan. As a result, "We haven't had time to do a post mortem," according to Laurie Little, Valeant's VP of investor relations, speaking at the Jefferies Global Healthcare Conference on 19 November. However, there's "no urgency" to get another big deal going. "We need a few days' rest," she said. "It would be good to string a few quiet quarters together."


FDA Generic Labeling Reg Could Fuel Suits Against Brands As Well

Proposed rule’s 30-day deadline for adoption of a generic’s approved label change could set standard for following brand’s revision; brands could be sued for picking one generic label change over another.

BioPharmaceutical United States

Five Prime launches $62.4m IPO; Aerie files to raise $57.5m

Five Prime Therapeutics priced its initial public offering on 17 September at $13 per share, in the middle of a previously announced range, and added 800,000 shares to raise an extra $10m from its IPO.

Cancer Japan

Bausch & Lomb Sold To Valeant Pharmaceuticals For $8.7 Billion

In the latest of more than a dozen acquisitions Valeant has made since it was created by a merger with Biovail SA in 2011, Valeant’s purchase of Bausch & Lomb will increase its eye care portfolio substantially.

Medical Device
See All

Company Information